<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput xmlns:ns2="local" hits="1" offset="0" totalResults="1"><SearchResults><Trial Id="207231"><Indications><Indication>Blepharospasm</Indication></Indications><CompaniesCollaborator><Company>National Institutes of Health Clinical Center</Company></CompaniesCollaborator><CompaniesSponsor><Company>National Institute of Neurological Disorders and Stroke</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-10-11T00:00:00Z</DateChangeLast><DateStart>2007-07-09T00:00:00Z</DateStart><Identifiers><Identifier>07-N-0191</Identifier><Identifier>070191</Identifier><Identifier>NCT00500799</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>electromyography alone</Intervention><Intervention>transcranial magnetic stimulation alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>72</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study examined the role of certain areas of the brain in blepharospasm, a type of dystonia that causes unwanted or uncontrollable blinking or closing of the eyelids. The study compared brain activity in healthy subjects and in subjects with blepharospasm to find differences in the brain that may lead to better treatments for dystonia. This proposal evaluated the role of an increase in excitability of the orbicularis oculi (OO) muscle representation in the medial frontal areas (supplementary</Teaser><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Prospective</Term></TermsDesign><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Brain Changes in Blepharospasm</TitleDisplay><PatientSegmentTerms><PatientSegment>Blepharospasm - Subjects with Benign Essential Blepharospasm(BEB)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cingulate cortex </BiomarkerName><BiomarkerName> Motor evoked potential </BiomarkerName><BiomarkerName> Supplementary motor cortex</BiomarkerName></BiomarkerNames><PrimaryCompletionDate></PrimaryCompletionDate><NumberOfSites>1</NumberOfSites></Trial></SearchResults></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput>